Rankings / Hormones & Endocrine
Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant)
Hormones & Endocrine · SERM / estrogen receptor modulator
Tier C+
Bottom line
Read Off Label grades Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant) as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.
WADA coverage: bazedoxifene, clomifene/clomiphene, cyclofenil, elacestrant, fulvestrant, ospemifene, raloxifene, tamoxifen and toremifene.
Studied, labeled, or reported-use context: Clinical dosing varies by indication; no healthy optimization dose — Rx; WADA S4 prohibited; not individualized guidance.
What the evidence says
WADA coverage: bazedoxifene, clomifene/clomiphene, cyclofenil, elacestrant, fulvestrant, ospemifene, raloxifene, tamoxifen and toremifene. Clomiphene and enclomiphene keep their individual rows; this row covers the broader WADA anti-estrogen class.
Mechanism
SERMs and anti-estrogens modulate estrogen receptor signaling or estrogen feedback; bodybuilding use often targets post-cycle HPG-axis recovery or gynecomastia control.
Studied, labeled, or reported dose & route
Clinical dosing varies by indication; no healthy optimization dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant)'s effects?
- Read Off Label rates the evidence for Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant) as Moderate and the benefit magnitude as med, producing an overall grade of C+ (5.5/10). WADA coverage: bazedoxifene, clomifene/clomiphene, cyclofenil, elacestrant, fulvestrant, ospemifene, raloxifene, tamoxifen and toremifene.
- What safety findings are reported for Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant)?
- Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant) has a med risk profile in the database. Med (VTE risk for some, hot flashes, endometrial effects depending agent, ocular/liver effects, drug interactions) Legal status: Rx; WADA S4 prohibited.
- What doses or routes are reported for Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant)?
- Clinical dosing varies by indication; no healthy optimization dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Other SERMs / anti-estrogens (tamoxifen / raloxifene / fulvestrant) work?
- SERMs and anti-estrogens modulate estrogen receptor signaling or estrogen feedback; bodybuilding use often targets post-cycle HPG-axis recovery or gynecomastia control.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.